Shanghai Yiweikang Pharmaceutical Co. Ltd. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, inflammatory and immunological disorders.
Insilico Medicine Hong Kong Ltd. has synthesized ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer and viral infection.
Sravathi AI Technology Pvt Ltd. has disclosed ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
A Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. patent describes new ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer
Shanghai Haihe Biopharma Co. Ltd. has disclosed phosphonic acid derivatives and their prodrugs reported to be useful for the treatment of cancer and infections.
China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have patented benzimidazole compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Innovstone Therapeutics Ltd. has described aromatic heterocyclic compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors potentially useful for the treatment of pancreatic cancer, heart failure and myocardial infarction.
Shanghai Haihe Biopharma Co. Ltd. has disclosed hydroxamic acid compounds acting as ENPP1 inhibitors reported to be useful for the treatment of cancer and infections.
